Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2010

01.01.2010 | Preclinical Study

Decreased TGFβ signaling and increased COX2 expression in high risk women with increased mammographic breast density

verfasst von: Wei Tse Yang, Michael T. Lewis, Kenneth Hess, Helen Wong, Anna Tsimelzon, Nese Karadag, Michelina Cairo, Caimaio Wei, Funda Meric-Bernstam, Powel Brown, Banu Arun, Gabriel N. Hortobagyi, Aysegul Sahin, Jenny C. Chang

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

High mammographic density is associated with a increased risk of breast cancer. We hypothesized that specific pathways exist that are associated with increased mammographic density, and may therefore be used to identify potential targets for chemoprevention. Histologically confirmed normal breast tissue was collected from women undergoing breast surgery who had available demographic data and mammograms for review. Women with low versus high mammographic breast density were compared. Differentially expressed genes using Affymetrix HG U133Plus2 chips were identified in dense versus non-dense tissue. Immunohistochemical analysis (IHC) of estrogen receptor, progesterone receptor, Ki67, and COX2 expression was performed. About 66 women were identified, 28 (42%) had high, and 38 (58%) had low mammographic density. About 73 genes had differential expression between normal breast tissue with high and low mammographic density (< 0.001, fold change ≥1.5with a low false discovery rate (<10%). Network and canonical pathway analysis indicated decreased TGFβ signaling (TGFBR2, SOS, SMAD3, CD44 and TNFRSF11B) in dense breast tissue relative to non-dense breast. By IHC, only COX2 expression in the stroma was statistically significant on multivariate analysis. TGFβ ligands are currently the only growth factors known to prevent mammary epithelial cell proliferation. TGFβ signaling has been reported to be inhibited by COX-2, and these molecules are highly differentially expressed in individuals at high risk of developing breast cancer. These results strongly suggest that COX2 inhibition should be investigated for breast cancer prevention despite possible increase in cardiovascular risk.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Atkinson C, Warren R, Bingham SA, Day NE (1999) Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen. Cancer Epidemiol Biomarkers Prev 8(10):863–866PubMed Atkinson C, Warren R, Bingham SA, Day NE (1999) Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen. Cancer Epidemiol Biomarkers Prev 8(10):863–866PubMed
2.
Zurück zum Zitat Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB et al (1995) Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 87(9):670–675. doi:10.1093/jnci/87.9.670 CrossRefPubMed Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB et al (1995) Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 87(9):670–675. doi:10.​1093/​jnci/​87.​9.​670 CrossRefPubMed
3.
Zurück zum Zitat Boyd NF, Dite GS, Stone J, Gunasekara A, English DR, McCredie MR et al (2002) Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med 347(12):886–894. doi:10.1056/NEJMoa013390 CrossRefPubMed Boyd NF, Dite GS, Stone J, Gunasekara A, English DR, McCredie MR et al (2002) Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med 347(12):886–894. doi:10.​1056/​NEJMoa013390 CrossRefPubMed
5.
Zurück zum Zitat Boyd NF, Lockwood GA, Martin LJ, Byng JW, Yaffe MJ, Tritchler DL (2001) Mammographic density as a marker of susceptibility to breast cancer: a hypothesis. IARC Sci Publ 154:163–169PubMed Boyd NF, Lockwood GA, Martin LJ, Byng JW, Yaffe MJ, Tritchler DL (2001) Mammographic density as a marker of susceptibility to breast cancer: a hypothesis. IARC Sci Publ 154:163–169PubMed
6.
Zurück zum Zitat Boyd NF, Lockwood GA, Martin LJ, Knight JA, Jong RA, Fishell E et al (1999) Mammographic densities and risk of breast cancer among subjects with a family history of this disease. J Natl Cancer Inst 91(16):1404–1408. doi:10.1093/jnci/91.16.1404 CrossRefPubMed Boyd NF, Lockwood GA, Martin LJ, Knight JA, Jong RA, Fishell E et al (1999) Mammographic densities and risk of breast cancer among subjects with a family history of this disease. J Natl Cancer Inst 91(16):1404–1408. doi:10.​1093/​jnci/​91.​16.​1404 CrossRefPubMed
7.
Zurück zum Zitat Boyd NF, Martin LJ, Li Q, Sun L, Chiarelli AM, Hislop G et al (2006) Mammographic density as a surrogate marker for the effects of hormone therapy on risk of breast cancer. Cancer Epidemiol Biomarkers Prev 15(5):961–966. doi:10.1158/1055-9965.EPI-05-0762 CrossRefPubMed Boyd NF, Martin LJ, Li Q, Sun L, Chiarelli AM, Hislop G et al (2006) Mammographic density as a surrogate marker for the effects of hormone therapy on risk of breast cancer. Cancer Epidemiol Biomarkers Prev 15(5):961–966. doi:10.​1158/​1055-9965.​EPI-05-0762 CrossRefPubMed
8.
Zurück zum Zitat Byng JW, Yaffe MJ, Jong RA, Shumak RS, Lockwood GA, Tritchler DL et al (1998) Analysis of mammographic density and breast cancer risk from digitized mammograms. Radiographics 18(6):1587–1598PubMed Byng JW, Yaffe MJ, Jong RA, Shumak RS, Lockwood GA, Tritchler DL et al (1998) Analysis of mammographic density and breast cancer risk from digitized mammograms. Radiographics 18(6):1587–1598PubMed
11.
Zurück zum Zitat Chen J, Pee D, Ayyagari R, Graubard B, Schairer C, Byrne C et al (2006) Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst 98(17):1215–1226PubMedCrossRef Chen J, Pee D, Ayyagari R, Graubard B, Schairer C, Byrne C et al (2006) Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst 98(17):1215–1226PubMedCrossRef
12.
Zurück zum Zitat Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW (2004) Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 96(8):621–628PubMed Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW (2004) Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 96(8):621–628PubMed
13.
Zurück zum Zitat Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371–1388. doi:10.1093/jnci/90.18.1371 CrossRefPubMed Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371–1388. doi:10.​1093/​jnci/​90.​18.​1371 CrossRefPubMed
14.
Zurück zum Zitat Freedman M, San Martin J, O’Gorman J, Eckert S, Lippman ME, Lo SC et al (2001) Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. J Natl Cancer Inst 93(1):51–56. doi:10.1093/jnci/93.1.51 CrossRefPubMed Freedman M, San Martin J, O’Gorman J, Eckert S, Lippman ME, Lo SC et al (2001) Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. J Natl Cancer Inst 93(1):51–56. doi:10.​1093/​jnci/​93.​1.​51 CrossRefPubMed
17.
Zurück zum Zitat Chlebowski RT, McTiernan A (2003) Biological significance of interventions that change breast density. J Natl Cancer Inst 95(1):4–5PubMed Chlebowski RT, McTiernan A (2003) Biological significance of interventions that change breast density. J Natl Cancer Inst 95(1):4–5PubMed
18.
Zurück zum Zitat van Gils CH, Hendriks JH, Holland R, Karssemeijer N, Otten JD, Straatman H et al (1999) Changes in mammographic breast density and concomitant changes in breast cancer risk. Eur J Cancer Prev 8(6):509–515. doi:10.1097/00008469-199912000-00006 PubMed van Gils CH, Hendriks JH, Holland R, Karssemeijer N, Otten JD, Straatman H et al (1999) Changes in mammographic breast density and concomitant changes in breast cancer risk. Eur J Cancer Prev 8(6):509–515. doi:10.​1097/​00008469-199912000-00006 PubMed
19.
Zurück zum Zitat van Gils CH, Otten JD, Hendriks JH, Holland R, Straatman H, Verbeek AL (1999) High mammographic breast density and its implications for the early detection of breast cancer. J Med Screen 6(4):200–204PubMed van Gils CH, Otten JD, Hendriks JH, Holland R, Straatman H, Verbeek AL (1999) High mammographic breast density and its implications for the early detection of breast cancer. J Med Screen 6(4):200–204PubMed
20.
Zurück zum Zitat BI-RADS (2003)BI-RADS. American College of Radiology, Reston, VA BI-RADS (2003)BI-RADS. American College of Radiology, Reston, VA
21.
Zurück zum Zitat Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R et al (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362(9381):362–369. doi:10.1016/S0140-6736(03)14023-8 CrossRefPubMed Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R et al (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362(9381):362–369. doi:10.​1016/​S0140-6736(03)14023-8 CrossRefPubMed
23.
Zurück zum Zitat Forrester E, Chytil A, Bierie B, Aakre M, Gorska AE, Sharif-Afshar AR et al (2005) Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res 65(6):2296–2302. doi:10.1158/0008-5472.CAN-04-3272 CrossRefPubMed Forrester E, Chytil A, Bierie B, Aakre M, Gorska AE, Sharif-Afshar AR et al (2005) Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res 65(6):2296–2302. doi:10.​1158/​0008-5472.​CAN-04-3272 CrossRefPubMed
24.
Zurück zum Zitat Thirunavukkarasu K, Miles RR, Halladay DL, Yang X, Galvin RJ, Chandrasekhar S et al (2001) Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. J Biol Chem 276(39):36241–36250. doi:10.1074/jbc.M104319200 CrossRefPubMed Thirunavukkarasu K, Miles RR, Halladay DL, Yang X, Galvin RJ, Chandrasekhar S et al (2001) Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. J Biol Chem 276(39):36241–36250. doi:10.​1074/​jbc.​M104319200 CrossRefPubMed
28.
Zurück zum Zitat Uttamsingh S, Bao X, Nguyen KT, Bhanot M, Gong J, Chan JL et al (2008) Synergistic effect between EGF and TGF-beta1 in inducing oncogenic properties of intestinal epithelial cells. Oncogene 27(18):2626–2634. doi:10.1038/sj.onc.1210915 CrossRefPubMed Uttamsingh S, Bao X, Nguyen KT, Bhanot M, Gong J, Chan JL et al (2008) Synergistic effect between EGF and TGF-beta1 in inducing oncogenic properties of intestinal epithelial cells. Oncogene 27(18):2626–2634. doi:10.​1038/​sj.​onc.​1210915 CrossRefPubMed
29.
Zurück zum Zitat Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E et al (2001) Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276(21):18563–18569. doi:10.1074/jbc.M010787200 CrossRefPubMed Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E et al (2001) Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276(21):18563–18569. doi:10.​1074/​jbc.​M010787200 CrossRefPubMed
30.
Zurück zum Zitat Subbaramaiah K, Hudis C, Chang SH, Hla T, Dannenberg AJ (2008) EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange. J Biol Chem 283(6):3433–3444. doi:10.1074/jbc.M705409200 CrossRefPubMed Subbaramaiah K, Hudis C, Chang SH, Hla T, Dannenberg AJ (2008) EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange. J Biol Chem 283(6):3433–3444. doi:10.​1074/​jbc.​M705409200 CrossRefPubMed
31.
Zurück zum Zitat Chang MC, Wu HL, Lee JJ, Lee PH, Chang HH, Hahn LJ et al (2004) The induction of prostaglandin E2 production, interleukin-6 production, cell cycle arrest, and cytotoxicity in primary oral keratinocytes and KB cancer cells by areca nut ingredients is differentially regulated by MEK/ERK activation. J Biol Chem 279(49):50676–50683. doi:10.1074/jbc.M404465200 CrossRefPubMed Chang MC, Wu HL, Lee JJ, Lee PH, Chang HH, Hahn LJ et al (2004) The induction of prostaglandin E2 production, interleukin-6 production, cell cycle arrest, and cytotoxicity in primary oral keratinocytes and KB cancer cells by areca nut ingredients is differentially regulated by MEK/ERK activation. J Biol Chem 279(49):50676–50683. doi:10.​1074/​jbc.​M404465200 CrossRefPubMed
32.
Zurück zum Zitat Chang SH, Liu CH, Conway R, Han DK, Nithipatikom K, Trifan OC et al (2004) Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci USA 101(2):591–596. doi:10.1073/pnas.2535911100 CrossRefPubMed Chang SH, Liu CH, Conway R, Han DK, Nithipatikom K, Trifan OC et al (2004) Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci USA 101(2):591–596. doi:10.​1073/​pnas.​2535911100 CrossRefPubMed
36.
Metadaten
Titel
Decreased TGFβ signaling and increased COX2 expression in high risk women with increased mammographic breast density
verfasst von
Wei Tse Yang
Michael T. Lewis
Kenneth Hess
Helen Wong
Anna Tsimelzon
Nese Karadag
Michelina Cairo
Caimaio Wei
Funda Meric-Bernstam
Powel Brown
Banu Arun
Gabriel N. Hortobagyi
Aysegul Sahin
Jenny C. Chang
Publikationsdatum
01.01.2010
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0350-0

Weitere Artikel der Ausgabe 2/2010

Breast Cancer Research and Treatment 2/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.